Seo tags
SEO
Products
Calcium dobesilate （with GMP,DMF open and closed parts）
English name: Calcium dobesilate CAS No.: 20123-80-2 Molecular formula: C12H10CaO10S2 · H2O Application category: capillary protective agent
隐藏域元素占位
Allopurinol （with GMP,DMF open and closed parts）
English name: Allopurinol CAS No.: 315-30-0 Molecular formula: C5H4N4O Application category: anti gout drugs
隐藏域元素占位
English name: Posaconazole CAS No.: 171228-49-2 Molecular formula: C37H42F2N8O4 Application category: antifungal drug substance
隐藏域元素占位
3-Amino-4-pyrazolecarboxamide hemisulfate
English name: 3-Amino-4-pyrazolecarboxamide hemisulfate CAS No.: 27511-79-1 Molecular formula: C8H14N8O6S
隐藏域元素占位
News
Linagliptin/metformin extended-release tablets (I), marketed under the brand name LedaTang®, is a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. and held as the marketing authorization holder; it is also the first extended-release formulation of its kind approved for marketing in China.
隐藏域元素占位
LE DA TANG is a pharmaceutical brand dedicated to the treatment of diabetes, with its flagship product being “LE DA TANG® Linagliptin–Metformin Extended-Release Tablets (I).” This combination antidiabetic formulation contains the DPP‑4 inhibitor linagliptin and the biguanide metformin hydrochloride. Manufactured by Hubei Guangchen Pharmaceutical Co., Ltd., it is the first domestically approved extended-release formulation of its kind, indicated for glycemic control in adult patients with type 2 diabetes who are suitable for treatment with both linagliptin and metformin.
隐藏域元素占位
Ledar Tang® Linagliptin-Metformin Extended-Release Tablets (I) are the first domestically approved extended-release formulation, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. This product combines the DPP‑4 inhibitor linagliptin with metformin hydrochloride; it is taken once daily, one tablet per dose, with meals, and is indicated, in conjunction with dietary management and exercise, for glycemic control in adult patients with type 2 diabetes who are suitable candidates for treatment with both linagliptin and metformin.
隐藏域元素占位
Recently, Hubei Guangchen Pharmaceutical Co., Ltd. successfully obtained Level 2 (Managed) certification under the Data Management Capability Maturity Model (DCMM), signifying that the company has established a standardized data management system and possesses foundational data management capabilities. Moving forward, the company will deepen the integration of data with business functions such as quality control, production management, safety management, human resources, and corporate decision-making, thereby providing robust data support for the enterprise’s sustained, high-quality development.
隐藏域元素占位
Hubei Guangchen Pharmaceutical Co., Ltd. Held a Grand 2025 Work Summary Conference
On January 18, 2026, Comrade Chen Shaoyan, General Manager of the company, chaired the 2025 Work Summary Meeting of Hubei Guangchen Pharmaceutical Co., Ltd. in the company’s second-floor conference room. The meeting was attended by the company’s shareholders and management personnel at or above the department head level. During the meeting, heads of various departments gave a comprehensive summary of their respective departments’ achievements in 2025, identified existing problems, and proposed improvement measures. General Manager Comrade Chen Shaoyan then laid out the company’s key tasks for 2026 in detail.
隐藏域元素占位
Carefully develop drugs with special indications using proprietary technology
Customer Service Hotline
Official website: www.hbgcyy.cn
Address: No. 19, Biopark 2nd Road, Biopark Industrial Park, High-tech Zone, Yichang City.
This website supports both IPV4 and IPV6 access.
Copyright © 2023 Guangchen Pharmaceutical ALL RIGHTS RESERVED.